EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access · CC BY-NC-ND 4.0

Neoadjuvant Capecitabine in Operable HPV‐Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting

Marco A Mascarella iD, Keith Richardson, Alex Mlynarek, Michael P Hier, Derin Caglar, Livia Florianova, Marc Philippe Pusztaszeri, Khalil Sultanem, Nader Sadeghi, Nathaniel Bouganim, Khashayar Esfahani

Otolaryngology–Head and Neck Surgery · 2024

DOI: 10.1002/ohn.1003 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Otolaryngology–Head and Neck Surgery, 2024. Verfasst von Marco A Mascarella und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada. Hauptthemen laut MEDLINE: Head and Neck Neoplasms, Neoadjuvant Therapy, Capecitabine. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

Limited progress has occurred in treating operable human papillomavirus (HPV)‐negative head and neck squamous cell carcinoma (HNSCC). Accessing timely care remains challenging in public health care systems, potentially resulting in disease progression before treatment initiation. Study Design A prospective cohort of patients receiving neoadjuvant capecitabine (NC) was compared to stage‐matched patients undergoing standard of care (SC).

Setting

This study was performed at 2 academic centers in Montreal, Canada.

Methods

To ascertain the effect of 2 cycles of NC in operable HPV‐negative HNSCC patients on clinical‐to‐pathologic stage migration. Comparison to an SC group was performed to site and TNM stage matched patients. Pathologic treatment response was measured using the modified Ryan score.

Results

We compared 16 NC patients (11 oral cavity, 3 skin, 2 larynx) with 32 SC patients. Ten NC patients exhibited a pathologic response (1 complete, 3 major, 6 minor). Clinical‐to‐pathologic stage migration differed significantly between NC and SC groups: downstage (6 vs 1), upstage (3 vs 14), no change (7 vs 17, P = .0047). There was no severe treatment toxicity related to capecitabine. All patients in the NC group underwent surgery.

Conclusion

NC followed by surgery demonstrates measurable pathologic response in HPV‐negative HNSCC, suggesting potential utility in resource‐limited health care settings.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Head and Neck NeoplasmsNeoadjuvant TherapyCapecitabineHumansMaleFemaleMiddle AgedProspective StudiesAgedCarcinoma, Squamous CellAntimetabolites, AntineoplasticFluorouracilNeoplasm StagingTreatment OutcomeSquamous Cell Carcinoma of Head and NeckDeoxycytidineAdult

Stichwörter der Autor:innen

HPV‐negative cancerhealth care systemneoadjuvant capecitabinepathologic responsestage migrationsurgery

Substanzen

CapecitabineAntimetabolites, AntineoplasticFluorouracilDeoxycytidine

Autor:innen und Institutionen

  • Department of Otolaryngology-Head and Neck Surgery, McGill University, Montreal, Canada.
  • Centre for Clinical Epidemiology, Lady Davis Institute of the Jewish General Hospital, Montreal, Canada.
  • McGill Centre for Translational Research in Cancer, McGill University, Montreal, Canada.
  • Department of Anatomical Pathology, McGill University, Montreal, Canada.
  • Division of Radiation Oncology, Department of Oncology, Jewish General Hospital, Montreal, Canada.
  • Division of Medical Oncology, Department of Medicine, McGill University, Montreal, Canada.

ORCID-Profile: Marco A Mascarella

Zitieren

APA

Mascarella, M. A., Richardson, K., Mlynarek, A., Hier, M. P., Caglar, D., Florianova, L., Pusztaszeri, M. P., Sultanem, K., Sadeghi, N., Bouganim, N., & Esfahani, K. (2024). Neoadjuvant Capecitabine in Operable HPV‐Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting. Otolaryngology–Head and Neck Surgery. https://doi.org/10.1002/ohn.1003

Vancouver

Mascarella MA, Richardson K, Mlynarek A, Hier MP, Caglar D, Florianova L, et al. Neoadjuvant Capecitabine in Operable HPV‐Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting. Otolaryngology–Head and Neck Surgery. 2024. doi:10.1002/ohn.1003

BibTeX
@article{Mascarella2024,
  author = {Mascarella, Marco A and Richardson, Keith and Mlynarek, Alex and Hier, Michael P and Caglar, Derin and Florianova, Livia and Pusztaszeri, Marc Philippe and Sultanem, Khalil and Sadeghi, Nader and Bouganim, Nathaniel and Esfahani, Khashayar},
  title = {Neoadjuvant Capecitabine in Operable HPV‐Negative Head and Neck Cancer: Fortuitous Findings in a Resource Constrained Setting},
  journal = {Otolaryngology–Head and Neck Surgery},
  year = {2024},
  doi = {10.1002/ohn.1003}
}
Kostenlos starten →